MediWound to Report Second Quarter 2024 Financial Results
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
东部时间8:30 am于8月14日星期三设有电话会议和网络直播。
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024.
以色列亚夫兰,2024年8月2日,环球新闻社 – 媒体溃疡有限公司(纳斯达克股票代码:MDWD),全球下一代酶治疗组织修复领域的领导者,今天宣布公司将于2024年8月14日星期三发布截至2024年6月30日第二季度的财务报告。
Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.
报告发布后,管理层将于美国东部时间上午8:30举行电话会议和网络直播,讨论财务结果、提供公司更新事项并回答问题。
Dial-in and call details are as follows:
拨打电话的详细信息如下:
Conference Call & Webcast Details | |
Toll-Free: | 1-833-630-1956 |
Israel: | 1-80-921-2373 |
International: | 1-412-317-1837 |
Webcast: | Click HERE |
电话会议和网络研讨会详情 | |
免费电话: | 1-833-630-1956 |
以色列: | 1-80-921-2373 |
国际: | 1-412-317-1837 |
网络直播: | 点击这里 |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
参与者应在电话会议开始前至少5分钟拨打上述适用的电话号码。
About MediWound
关于mediwound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
mediwound(Nasdaq:MDWD)是全球非手术组织修复创新酵素治疗领域的领导者。公司专注于开发、生产和销售快速而有效的生物制品,以提高现有的护理标准和患者体验,并降低成本和不必要的手术。
MediWound's first drug, NexoBrid, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company's lead drug under development, EscharEx. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market.
MediWound的首款药物NexoBrid是FDA和EMA批准的孤儿生物制品,用于去除深部部分厚度和/或全厚度烧伤组织,可以显著减少手术干预。利用相同的核心生物治疗酶平台技术,MediWound开发了强大的研发管道,包括该公司正在开发的领先药物EscharEx。 EscharEx是一种为患者消除慢性伤口的生物治疗药物,为市场带来了重大潜力,并提供了重要的潜在优势。
For more information visit and follow the Company on LinkedIn.
获取更多信息,请访问并在社交媒体上关注公司。LinkedIn.
MediWound Contacts: | |
Hani Luxenburg | Daniel Ferry |
Chief Financial Officer | Managing Director |
MediWound Ltd. | LifeSci Advisors, LLC |
ir@mediwound.com | daniel@lifesciadvisors.com |
Media Contact: | |
Ellie Hanson | |
FINN Partners for MediWound | |
ellie.hanson@finnpartners.com | |
929-588-2008 |
MediWound联系人: | |
Hani Luxenburg | Daniel Ferry |
致富金融(临时代码) | 董事总经理 |
MediWound Ltd. | LifeSci Advisors,LLC |
ir@mediwound.com | daniel@lifesciadvisors.com |
媒体联系人: | |
Ellie Hanson | |
MediWound的FINN合作伙伴 | |
ellie.hanson@finnpartners.com | |
929-588-2008 |